Acadia Pharmaceuticals Inc. (ACAD)

[gi197845]

LOL, $15.05 after hours now!

[gi197845]

Have you taken to shorting ACAD? Or are you a buy, buy, buy, guy now? You do release that the shorts have increased their position, right? You do realize that when this goes even much lower, after a 2nd Joe Biden FDA rejection, that a reverse split is coming that will wipe out any potential profit you had, right...Right, genius?

[gi197845]

How much are you down on ACAD, AVEO and POTN?

[harry crumb]

U hav no clue loser

[harry crumb]

Get lost loser

[gi197845]

Harry Bumb, Buy, Buy, Buy!!! and vote again for JB or KAMALA! Apparently you've never been through a recession or a depression! Keep investing in penny stock picks, penny stock picks! Waterless toothbrush from a used car salesmen! LOOOOOL!

[gi197845]

Buy, buy, buy, before the dilution, before the reverse split, before the FDA rejection, before the recession turns to a great democrat reset depression!

[gi197845]

If they drop this to -5$ I'm a buyer!!!

[gi197845]

Buy, buy, buy @ $16.69 now!

[gi197845]

LOL, you were so wrong as usual! It's so far below 22/21, so you need to load! Load now and vote JB! Sell your lots for less then you bout them for, libby!

[gi197845]

Buy more Harry Crumb, catch this falling knife, invest life's saving!

[gi197845]

So ACDA or as I called it now, EEEGAAADSs, continues to under perform, why did the stock price rise in after hours trading? Also, did Steve Davis have the front of his shirt fully unbuttoned this time, during the conference call? If so, when the next Q under performs and misses, he won't even be wearing any shirt and we'll be able to see his pierced nipples, just like ex-GOV Cumouo! The next following Q and next Q to do worse and worse, Steve Davis, will be fully nude!

[gi197845]

Facts don't matter to the liberal FDA, only feelings matter, so Adam Feurstein and Brian Dunn will reject Nuplazid ADP a 2nd time!

[harry crumb]

Lmao, get in get out!

[IanFromSI]

What's your prediction for AdCom mtg?

Quality of life with Nuplazid was significantly improved for PDP pts.
i.e. T of Hallucinations, delusions and MDD in about a third of the pts suffering from MDD.

Surely ADP patients would benefit from an improved quality of life in their last years or months. ???


Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID(R) (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis Scheduled for June 17, 2022
2022-05-02 04:05:07 PM ET (BusinessWire)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has been scheduled for June 17, 2022. The target action date for the application is August 4, 2022.

"We appreciate our ongoing engagement with the FDA and look forward to a productive discussion on the clinical evidence supporting the positive benefit-risk profile for pimavanserin as a treatment for ADP at the upcoming Advisory Committee meeting," said Steve Davis, Chief Executive Officer. "The hallucinations and delusions that Alzheimer's patients endure represent one of the most significant burdens in this community, and one of the leading reasons for long-term care placement. There are no FDA-approved treatments for this critical public health need. Off-label use of multi-receptor acting antipsychotics with marginal efficacy and significant safety concerns can lead to poor patient outcomes, including worsening of cognition and motor function."

[gi197845]

Harry Crumb, please buy more, now that it's down to the 18's. Please put your lifes savings into this stock, before the next round of FDA rejections and before the approved dilution of 6,000,000,000 more shares!
https://ir.acadia-pharm.com/static-files/1c9815e6-709a-46b6-905d-7cfd32e0719a

Thank you.

[gi197845]

$18.84 now, hey isn't there a TV show 1884 ?

[gi197845]

Zero! 0 !

[gi197845]

Buy all you can at the $ 18.90 level!
How did POTN work out for ya?

[gi197845]

GI197845, thanks for your service. You were correct yet again, the bunion no funion pain study failed!

[gi197845]

When is the bunion no funion, failed pain study going to be publicly admitted to in a press release? Too bad Nuplazid sales keep going down and down, with no new patients...

[harry crumb]

Will load 21/22 area if they drop it

[gi197845]

What about the bunion, no funion pain study? It failed.

[LasNubes]

ACAD

Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)

-- Rett syndrome research to include oral presentation of Phase 3 Lavender trial and poster presentation highlighting the patient journey and clinical burden of the disease

-- E-poster presentation evaluating maintenance of efficacy and safety of pimavanserin among patients with Parkinson’s disease dementia with psychosis

March 22, 2022, 9:00 AM EDT
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.

[LasNubes]

Acadia Pharmaceuticals upgraded to buy at at Canaccord ahead of Nuplazid sNDA

Canaccord Genuity has upgraded Acadia Pharmaceuticals (ACAD +2.8%) to buy from hold citing the risk/reward presented by the company's sNDA for Nuplazid (pimavanserin) in Alzheimer's disease psychosis.

The firm upped its price target to $31 from $30 (~34% upside based on Tuesday's close).
Analyst Sumani Kulkarni said that the company's recent announcement that the U.S. FDA will hold an advisory committee and set an August action date for the sNDA is a positive.

He added that phase 2 ACP044 data for acute pain expected this quarter is "flying out investors' radar."

Kulkarni noted that Acadia (ACAD +2.8%) will submit an NDA for trofinetide mid-year for Rett syndrome, for which there is no FDA-approved therapy.

[gi197845]

Bunion, bunion, no funion!
I wonder when we'll be told that the pain test failed?

[gi197845]

ACAD does not have enough time left on the Nuplazid patent to do another P3 trial for ADP, so that's why we and ACAD are screwed, because the FDA will reject this a 2nd time around :(

[gi197845]

A real stinker-dinker day!

[gi197845]

It's been said the Nuplazid sales have peaked...
It would be an improvement if Nuplazid was submitted for sales overseas.
It would be an improvement if Nuplazid was approved in the USA for schizophrenia and of course DRP.
I realize Nuplazid can be prescribed off-label.
I predict the FDA will reject the 2nd sNDA for Nuplazid DRP.
I think ACAD has tried to grow too quickly with a giant sales force.
I think ACAD has tried to grow to quickly with their expensive, multi-million dollar, new research center in Sweden.
Acadia has an "open-shirt" style of management.
Get ready for the Acadia stock price to drop more and more.
Get ready for the dem government to fully take over healthcare and screw over profits.
Get ready for the big drop and the great reset, so we are all poor poppers to our elite and rich government leaders...

[gi197845]

Uh Oh, revenue miss and lowered expectations.
A perfect storm would be WWIII.
Pain bunion miss.
sNDA rejected.

[LasNubes]

Bunionectomy data should be coming up soon.
Their non-opioid pain asset alone could easily be worth much more than the rest of the company combined .


Just MHO

[gi197845]

What be happenin?

[georgejjl]

What is the expected peak sales per year for trofinetide for the treatment of Rett syndrome?

Good luck and GOD bless,

[LasNubes]

The recent movement here suggests the pain data will be very favorable. Buckle up.

[gi197845]

Good answer.
Thank you.

[harry crumb]

The BB's know what science they have, or they would never have bought into this. That alone is worthy of a investment. Do your own DD an trade smart, wealth comes to those who have patience. GL

[gi197845]

Hello Sir!
How do you think the pain, bunion trial results will go?
Do you think the end points will be met?
Thank you.

[LasNubes]

ACAD making moves this week. Data on pain study due out soon .

[harry crumb]

It will imo

[gi197845]

Do u still think it will climb to $30 in the short term? What about the expensive partnership, the end to quantitative easing and the socialist medicine/dem controlled, anti-capitalistic climate?

[gi197845]

ACADIA Pharmaceuticals and Stoke Therapeutics (STOK) announce collaboration for novel RNA-based medicines
7:14 AM ET 1/10/22 | Briefing.com
The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest.Terms of Collaboration
Under the terms of the agreement, Stoke will receive an upfront payment of $60 million from Acadia and is eligible to receive up to $907 million in milestones as well as royalties on future sales. For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits. In addition, Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones. For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels.

[harry crumb]

Interesting partnership announced. More for future pipeline scenario's.

[harry crumb]

Hard to say, if their products sell they make money, if they make money an new prifucts they make more money, thus the valuation goes up an values the pps so to early to tell, i feel its definately a 30+ stock as of now imo

[gi197845]

What affect will the FED have with stopping quantitative easing, not putting 100 billion a month into bonds and ETFs and not only slowing and stopping that, but selling off what it bought? Will stocks in general go down? Will ACAD crash or be effected?

[harry crumb]

Should climb over 30+ pps in short term

[LasNubes]

$24.39 with a price target of $28.
I’ll take it!

[harry crumb]

We are to

[harry crumb]

Its all BS, the street! Cramer an his idiots

[LasNubes]

I guess the street didn’t like the conference call regarding resubmission ?

I’m a buyer today on the re-trace!

[harry crumb]

Told people to buy at 20! We did $$$$$